AU2006214325B2 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells - Google Patents
Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells Download PDFInfo
- Publication number
- AU2006214325B2 AU2006214325B2 AU2006214325A AU2006214325A AU2006214325B2 AU 2006214325 B2 AU2006214325 B2 AU 2006214325B2 AU 2006214325 A AU2006214325 A AU 2006214325A AU 2006214325 A AU2006214325 A AU 2006214325A AU 2006214325 B2 AU2006214325 B2 AU 2006214325B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- skin
- antagonist
- cla
- cutaneous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 title claims abstract description 25
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 title claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 36
- 201000010099 disease Diseases 0.000 title abstract description 32
- 230000001404 mediated effect Effects 0.000 title abstract description 16
- 210000004027 cell Anatomy 0.000 title description 115
- 102100021596 Interleukin-31 Human genes 0.000 claims abstract description 194
- 101710181613 Interleukin-31 Proteins 0.000 claims abstract description 193
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 135
- 239000005557 antagonist Substances 0.000 claims abstract description 51
- 208000003251 Pruritus Diseases 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 20
- 201000004384 Alopecia Diseases 0.000 claims abstract description 19
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 18
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 201000004700 rosacea Diseases 0.000 claims abstract description 16
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 14
- 201000009053 Neurodermatitis Diseases 0.000 claims abstract description 14
- 208000017940 prurigo nodularis Diseases 0.000 claims abstract description 14
- 206010034277 Pemphigoid Diseases 0.000 claims abstract description 13
- 208000000594 bullous pemphigoid Diseases 0.000 claims abstract description 13
- 231100000360 alopecia Toxicity 0.000 claims abstract description 12
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims abstract description 11
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims abstract description 11
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims abstract description 11
- 230000003111 delayed effect Effects 0.000 claims abstract description 11
- 241000700584 Simplexvirus Species 0.000 claims abstract description 9
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims abstract description 8
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 8
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims abstract description 8
- 201000005962 mycosis fungoides Diseases 0.000 claims abstract description 8
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 107
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 100
- 229920001184 polypeptide Polymers 0.000 claims description 88
- 230000027455 binding Effects 0.000 claims description 28
- 208000017520 skin disease Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 230000013727 interleukin-31 production Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000004797 therapeutic response Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 93
- 201000008937 atopic dermatitis Diseases 0.000 description 93
- 210000003491 skin Anatomy 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 60
- 241000699670 Mus sp. Species 0.000 description 59
- 102000004169 proteins and genes Human genes 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 28
- 125000000539 amino acid group Chemical group 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 23
- 238000001514 detection method Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 201000004681 Psoriasis Diseases 0.000 description 15
- 206010000496 acne Diseases 0.000 description 15
- 238000003364 immunohistochemistry Methods 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 208000002874 Acne Vulgaris Diseases 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 230000003472 neutralizing effect Effects 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 12
- 206010070834 Sensitisation Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 229940092253 ovalbumin Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000008313 sensitization Effects 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 201000004624 Dermatitis Diseases 0.000 description 11
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000007390 skin biopsy Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 230000005951 type IV hypersensitivity Effects 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000006748 scratching Methods 0.000 description 10
- 230000002393 scratching effect Effects 0.000 description 10
- 206010040882 skin lesion Diseases 0.000 description 10
- 231100000444 skin lesion Toxicity 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 7
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 7
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 210000005069 ears Anatomy 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010002386 Interleukin-3 Proteins 0.000 description 6
- 102000000646 Interleukin-3 Human genes 0.000 description 6
- 241000030538 Thecla Species 0.000 description 6
- 230000002391 anti-complement effect Effects 0.000 description 6
- 108010008730 anticomplement Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 210000003071 memory t lymphocyte Anatomy 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000037311 normal skin Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 230000001823 pruritic effect Effects 0.000 description 5
- 230000001185 psoriatic effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000000106 sweat gland Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101001043822 Mus musculus Interleukin-31 Proteins 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 102000045345 human IL31 Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- -1 Lif Proteins 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010037083 Prurigo Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000045410 human IL31RA Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- 101150070234 31 gene Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000017452 Epidermal disease Diseases 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000005705 Keratin-5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000012254 genetic linkage analysis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036736 holocrine secretion Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000043719 human OSMR Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 231100000647 material safety data sheet Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940062713 mite extract Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Virology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012202218A AU2012202218B2 (en) | 2005-02-14 | 2012-04-17 | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311405P | 2005-02-14 | 2005-02-14 | |
| US60/653,114 | 2005-02-14 | ||
| US71676205P | 2005-09-13 | 2005-09-13 | |
| US60/716,762 | 2005-09-13 | ||
| US74995205P | 2005-12-13 | 2005-12-13 | |
| US60/749,952 | 2005-12-13 | ||
| PCT/US2006/005327 WO2006088955A2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012202218A Division AU2012202218B2 (en) | 2005-02-14 | 2012-04-17 | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006214325A1 AU2006214325A1 (en) | 2006-08-24 |
| AU2006214325B2 true AU2006214325B2 (en) | 2012-04-05 |
Family
ID=36685803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006214325A Ceased AU2006214325B2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| AU2006214326A Ceased AU2006214326B2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006214326A Ceased AU2006214326B2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists |
Country Status (8)
| Country | Link |
|---|---|
| US (11) | US20060188500A1 (enExample) |
| EP (2) | EP1856150A2 (enExample) |
| JP (2) | JP4927762B2 (enExample) |
| AU (2) | AU2006214325B2 (enExample) |
| CA (2) | CA2595877A1 (enExample) |
| IL (3) | IL184734A (enExample) |
| MX (2) | MX2007009577A (enExample) |
| WO (2) | WO2006088956A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| AU7445900A (en) | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| SI2230299T1 (sl) | 2002-01-18 | 2012-07-31 | Zymogenetics Inc | Nov citokinski zcytor ligand |
| US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
| CA2594502A1 (en) * | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| JP2009528264A (ja) | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| CA2654623C (en) | 2006-06-08 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease |
| PL2594586T3 (pl) * | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US7799323B2 (en) * | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| MY185647A (en) * | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| CA2708251C (en) | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| MA43918A (fr) * | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CN112020511B (zh) | 2018-03-16 | 2025-07-04 | 硕腾服务有限责任公司 | 用于兽医用途的白介素-31单克隆抗体 |
| MA52011A (fr) | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
| JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ， リミテッド | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
| CN112190708B (zh) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
| WO2022049614A1 (ja) | 2020-09-01 | 2022-03-10 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060090A2 (en) * | 2002-01-18 | 2003-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
| US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| WO2003024484A1 (fr) * | 2001-09-14 | 2003-03-27 | Ono Pharmaceutical Co., Ltd. | Medicaments pour traiter le prurit |
| JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
| KR20040083416A (ko) | 2002-02-22 | 2004-10-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 지양제 |
| JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
| JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
| WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
| CA2594502A1 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| WO2007037137A1 (ja) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | 射出成形装置 |
| JP2009528264A (ja) * | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| PL2594586T3 (pl) * | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| CA2708251C (en) * | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
-
2006
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Not-in-force
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en not_active Ceased
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en active Active
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en active Active
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060090A2 (en) * | 2002-01-18 | 2003-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
| US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
| US20030224487A1 (en) * | 2002-01-18 | 2003-12-04 | Sprecher Cindy A. | Novel cytokine zcytor17 ligand |
Non-Patent Citations (1)
| Title |
|---|
| Dillon, S. R. et al (2004) Nature Immunology 5(7): 752-760 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11312779B2 (en) | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions | |
| US8926957B2 (en) | Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells | |
| AU2012202218B2 (en) | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE COINVENTOR NAME FROM BILLSBOROUGH, JANINE TO BILSBOROUGH, JANINE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |